Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of EUR 1.19 billion. The enterprise value is 859.38 million.

Market Cap	1.19B
Enterprise Value	859.38M

Important Dates

The next estimated earnings date is Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	162.42M
Shares Outstanding	n/a
Shares Change (YoY)	+30.54%
Shares Change (QoQ)	-0.23%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	136.72M

Valuation Ratios

The trailing PE ratio is 3.30.

PE Ratio	3.30
Forward PE	n/a
PS Ratio	1.29
PB Ratio	37.07
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.47, with an EV/FCF ratio of -1.59.

EV / Earnings	2.39
EV / Sales	0.93
EV / EBITDA	2.47
EV / EBIT	2.74
EV / FCF	-1.59

Financial Position

The company has a current ratio of 2.36, with a Debt / Equity ratio of 6.07.

Current Ratio	2.36
Quick Ratio	2.16
Debt / Equity	6.07
Debt / EBITDA	0.56
Debt / FCF	-0.36
Interest Coverage	15.55

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	14.52%
Return on Invested Capital (ROIC)	467.59%
Return on Capital Employed (ROCE)	38.67%
Revenue Per Employee	964,841
Profits Per Employee	378,188
Employee Count	952
Asset Turnover	0.68
Inventory Turnover	47.58

Taxes

In the past 12 months, Novavax has paid 7.29 million in taxes.

Income Tax	7.29M
Effective Tax Rate	1.98%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	6.81
200-Day Moving Average	6.87
Relative Strength Index (RSI)	52.11
Average Volume (20 Days)	2,088

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.11

Income Statement

In the last 12 months, Novavax had revenue of EUR 918.53 million and earned 360.03 million in profits. Earnings per share was 2.17.

Revenue	918.53M
Gross Profit	525.26M
Operating Income	311.98M
Pretax Income	367.33M
Net Income	360.03M
EBITDA	346.99M
EBIT	311.98M
Earnings Per Share (EPS)	2.17

Full Income Statement

Balance Sheet

The company has 521.38 million in cash and 194.56 million in debt, giving a net cash position of 326.82 million.

Cash & Cash Equivalents	521.38M
Total Debt	194.56M
Net Cash	326.82M
Net Cash Per Share	n/a
Equity (Book Value)	32.04M
Book Value Per Share	0.20
Working Capital	451.61M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -537.25 million and capital expenditures -4.06 million, giving a free cash flow of -541.31 million.

Operating Cash Flow	-537.25M
Capital Expenditures	-4.06M
Free Cash Flow	-541.31M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 57.18%, with operating and profit margins of 33.96% and 39.20%.

Gross Margin	57.18%
Operating Margin	33.96%
Pretax Margin	39.99%
Profit Margin	39.20%
EBITDA Margin	37.78%
EBIT Margin	33.96%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.54%
Shareholder Yield	n/a
Earnings Yield	30.32%
FCF Yield	-45.58%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novavax has an Altman Z-Score of -1.72 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.72
Piotroski F-Score	5